With record-break­ing mpox vac­cine sales, Bavar­i­an Nordic buys trio of shots from Emer­gent for $270M cash

Bavar­i­an Nordic is putting some of its mpox vac­cine wind­falls to use, wa­ger­ing $270 mil­lion in cash to ac­quire three trav­el vac­cines — two of which are al­ready on the mar­ket — from Emer­gent BioSo­lu­tions.

It’s not just the port­fo­lio that Bavar­i­an Nordic is get­ting. The deal, which adds up to $380 mil­lion when you take in­to ac­count $110 mil­lion in mile­stones, will al­so give Bavar­i­an Nordic a set of US-based R&D fa­cil­i­ties, a Swiss-based bi­o­log­ics man­u­fac­tur­ing site, and com­mer­cial op­er­a­tions in both the US and the EU, com­plete with a spe­cial­ty sales­force.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER